Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been assigned a €79.00 ($91.86) price objective by equities research analysts at Goldman Sachs Group in a research report issued on Monday, April 1st, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. Goldman Sachs Group’s target price points to a potential upside of 8.37% from the stock’s current price.
Other equities analysts also recently issued reports about the company. Berenberg Bank set a €87.80 ($102.09) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Friday, December 7th. Nord/LB set a €82.00 ($95.35) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a report on Wednesday, February 20th. JPMorgan Chase & Co. set a €83.20 ($96.74) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a report on Thursday, December 20th. Jefferies Financial Group set a €68.00 ($79.07) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a report on Thursday, March 7th. Finally, Kepler Capital Markets set a €76.00 ($88.37) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a report on Thursday, February 21st. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of €82.90 ($96.40).
FME traded up €1.16 ($1.35) during trading on Monday, hitting €72.90 ($84.77). 639,929 shares of the company’s stock were exchanged, compared to its average volume of 704,197. The company has a market cap of $22.21 billion and a price-to-earnings ratio of 11.30. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of €55.44 ($64.47) and a fifty-two week high of €91.74 ($106.67). The company has a current ratio of 1.25, a quick ratio of 0.96 and a debt-to-equity ratio of 58.49.
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Article: What moving averages are used to define a golden cross?
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.